# Comparative Effectiveness, Safety, and Acceptability of Cannabis Use Disorder Treatments > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-use-disorder-treatment-research/ > **Published:** 2026-04-02T08:01:06-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:07:26-04:00 > **Clinical Summary:** Explore cannabis use disorder treatment research comparing pharmacological and psychosocial interventions for effectiveness, safety, and acceptability. --- CED Clinical Relevance  #84High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. 🔬 Evidence Watch  |  CED Clinic [Cannabis Use Disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/)[Addiction Treatment](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/)Psychosocial InterventionsPharmacotherapyNetwork Meta-Analysis Journal Addiction (Abingdon, England) Study Type Systematic Review Population Human participants Why This Matters [Cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) disorder affects millions globally, yet evidence-based treatment options remain limited and poorly defined. This network meta-analysis provides the first comprehensive comparison of all available pharmacological and psychosocial interventions, offering critical guidance for clinicians managing CUD. Clinical Summary This network meta-analysis examined 57 studies comparing pharmacological and psychosocial interventions for [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) in adults. The analysis included 6-36 studies per outcome measure, encompassing 260-3106 participants depending on the intervention category. Evidence for pharmacological interventions reducing [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) showed very high uncertainty, while psychosocial interventions demonstrated low-certainty evidence for benefit. The study assessed effectiveness through cannabis use levels, abstinence rates, adverse events, and treatment completion across different therapeutic approaches. Dr. Caplan’s Take “This confirms what I see clinically—we lack robust pharmacological options for cannabis use disorder, unlike other substance use disorders. The uncertainty around medication effectiveness underscores why I focus primarily on behavioral interventions and motivational approaches when patients present with problematic cannabis use.” Clinical Perspective 🧠 Clinicians should prioritize evidence-based psychosocial interventions as first-line treatment for cannabis use disorder. Given the limited and uncertain evidence for pharmacological approaches, medication should not be the primary treatment strategy, though supportive care for withdrawal symptoms may still have clinical utility. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Comparative%20effectiveness%2C%20safety%20and%20acceptability%20of%20pharmacological%20and%20psych...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41924869/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41924869/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Comparative%20effectiveness%2C%20safety%20and%20acceptability%20of%20pharmacological%20and%20psych...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41924869/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41924869/](https://pubmed.ncbi.nlm.nih.gov/41924869/) Table of Contents - [FAQ](#FAQ)[Are there effective medications for treating cannabis use disorder?](#Are_there_effective_medications_for_treating_cannabis_use_disorder) - [What psychosocial treatments work best for cannabis use disorder?](#What_psychosocial_treatments_work_best_for_cannabis_use_disorder) - [How should treatment completion rates influence my choice of cannabis use disorder treatment?](#How_should_treatment_completion_rates_influence_my_choice_of_cannabis_use_disorder_treatment) - [What does “low-certainty evidence” mean for clinical decision-making in cannabis use disorder treatment?](#What_does_8220low-certainty_evidence8221_mean_for_clinical_decision-making_in_cannabis_use_disorder_treatment) - [How significant are the treatment effects found in this study?](#How_significant_are_the_treatment_effects_found_in_this_study) - [Related](#Related) ## FAQ #### Are there effective medications for treating cannabis use disorder? According to this network meta-analysis of 57 studies, evidence for pharmacological interventions reducing cannabis use was very uncertain. Currently, there are no FDA-approved medications specifically for cannabis use disorder, and this research confirms the limited effectiveness of existing pharmacotherapies. #### What psychosocial treatments work best for cannabis use disorder? The study analyzed 6-16 psychosocial intervention studies involving up to 2,287 participants. #### How should treatment completion rates influence my choice of cannabis use disorder treatment? Treatment completion was one of the key outcomes measured in this analysis, as it directly impacts treatment effectiveness. The network meta-analysis compared acceptability across different interventions, though specific completion rates aren’t provided in the summary, suggesting clinicians should consider patient preferences and intervention tolerability. #### What does “low-certainty evidence” mean for clinical decision-making in cannabis use disorder treatment? Low-certainty evidence means there is limited confidence in the treatment effects, and future research may significantly change these conclusions. Clinicians should interpret results cautiously and consider individual patient factors when making treatment recommendations for cannabis use disorder. #### How significant are the treatment effects found in this study? The study used clinically meaningful difference thresholds (mean difference ±0.05, odds ratios ≤0.8 or ≥1.25) to determine significance. This approach ensures that reported effects are not just statistically significant but also represent meaningful clinical improvements that would impact patient outcomes in real-world practice. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta-analysis.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41924869/”, “about”: “addiction abingdon england systematic review comparative”, “isPartOf”: “Addiction (Abingdon, England)”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Psychosocial Interventions for Substance Use Disorder: A Systematic Review](https://cedclinic.com/substance-use-disorder-treatment-effectiveness-review/) A comprehensive review of therapeutic approaches and their clinical effectiveness in treating substance use disorders, including cannabis use disorder. [Read the Review](https://cedclinic.com/substance-use-disorder-treatment-effectiveness-review/) [PleoPharma Begins Phase 3 Trial for Cannabis Withdrawal Drug](https://cedclinic.com/pleopharma-begins-phase-3-trial-for-cannabis-withdrawal-drug/) Latest updates on a promising pharmacological treatment targeting [cannabis withdrawal symptoms](https://cedclinic.com/cannabis-use-disorder-risk-clinical-evidence/) in [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/). [Learn More](https://cedclinic.com/pleopharma-begins-phase-3-trial-for-cannabis-withdrawal-drug/) [Teen Substance Use Treatment Evidence](https://cedclinic.com/adolescent-substance-use-treatment-evidence/) Evidence-based insights into treatment options for adolescent substance use, including cannabis use disorder interventions. [Explore Insights](https://cedclinic.com/adolescent-substance-use-treatment-evidence/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).